All News
2017 Update of Treat to Target Recommendations for SpA/PsA
A 2017 international committee of experts met to assess and revise its earlier 2012 recommendations regarding treating to target in patients with psoriatic arthritis (PsA) and axial peripheral spondyloarthritis (SpA).
Read Article
The RheumNow Week in Review - 8 December 2017
Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.
Read Article
Infliximab Does Not Increase Perioperative Infection
Staying on a TNF inhibitor (TNFi) throughout major surgery has generatlly been associated with higher rates of perioperative infection (https://buff.ly/2iBFVjp). On the other hand, discontinuation of the TNFi prior to surgery is associated with lower ra
Read Article
Rheumatology Year in Review
During 2017, the improvements and refinements seen during previous years in the treatment of rheumatoid arthritis have been extending to other conditions ranging from psoriatic arthritis to lupus and for both monoclonal antibodies and oral small molecule medications.
Read Article
Do JAK Inhibitors Increase the Risk of Venous Thromboembolic Events?
Drug Safety has published a systematic review of the FDA’s Adverse Event Reporting System (FAERS) and finds numerous reports of thromboembolic adverse events (AEs) associated with two currently marketed Janus kinase (JAK) inhibitors, tofacitinib (Xeljanz) and ruxolitinib (Jakafi).
Read Article
Ixekizumab (Taltz) FDA Approved for Psoriatic Arthritis
On Friday, December 1st, the FDA approved Lilly's drug Taltz (ixekizumab) for use in adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Taltz, an IL-17 inhibitor, has previously been approved for plaque psoriasis where it has shown high level PASI75 and PASI100 responses.
Read Article
The ACR17 RheumNow Week in Review - 1 December 2017
Dr Jack Cush reviews nighlights and news from the past 2 weeks on RheumNow.com. This week's report includes new drug approvals, disappointing ACR guidelines, Lyme & Zika, infertility, dermatomyositis skin outcomes and myositis-associated cancer testing.
Read Article
ACR Clinical Guidelines Flawed by Low Evidence
JAMA Internal Medicine has reported that recommendations and clinical practice guidelines from the American College of Rheumatology are often based on expert opinion, but lack rigorous (grade A) evidence to support many of their recommendations.
Read Article
ACR17 Good News – Ankylosing Spondylitis and Spondyloarthritis
The following is a collection of AS/SpA-specific mentions culled from RheumNow's coverage of the Annual ACR 2017 meeting in San Diego.
Read Article
The RheumNow Week in Review - 17 November 2017
Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com. This week he covers FDA warnings on gout drugs, steroid use in Australia, biosimilars lost savings and methotrexate hepatotoxicity in psoriatic arthritis (PsA).
Read Article
MTX Doubles Hepatotoxicity Risk in Psoriasis Patients
A study from the University of Pennsylvania Perelman School of Medicine was published in the Journal of Investigative Dermatology showing that the risk of incident liver disease doubled when patients with psoriasis (PsO) or psoriatic arthritis (PsA) take methotrexate (MTX), but not when
Read Article
Podcast of ACR17 - Day 4
Care to learn what you missed at last weeks ACR 2017 meeting in San Diego? Here are 4 one hour audio podcasts - each with a compliation of 2-4 minute reports from Drs. Cush, Kavanaugh, the RheumNow Faculty and other rheumatology thought leaders and researchers. Another good way to learn from RheumNow.
Read Article
Podcast of ACR 17 - Day 3
Check out this compilation of our ACR17 Day 3 broadcasts, merged into a single one hour podcast !
Read Article
Several Agents Score on Radiographic Progression in Psoriatic Arthritis
Reduction on radiographic progression has now become the standard of care in the therapies used to treat psoriatic arthritis and, during the 2017 ACR Meeting, several agents reported the results of their studies with radiographic endpoints.
Read Article
My ACR Takeaways
With ACR 2017 winding down and the sheer volume of information seemingly overwhelming, I wanted to take the time to write an article regarding a few tips I learned that I will use in clinical practice.
IL-17 Inhibition with Secukinumab in PsA: X-Ray Outcomes
With the emergence of new MOAs for the treatment of psoriatic arthritis in recent years, the most burning question remained if newer agents would perform as well in terms of radiographic progression as they did in clinical domains.
Read Article
Who Are We Doing This For?
We take many things for granted. I walked 11,151 steps today going from sessions to posters and exhibit halls to learn as much as I can to take back to my clinic so I can help my patients. My feet were hurting, and my back bothered me as I tried to get comfortable for the next lecture; yet, these minor discomforts are nothing compared to what our patients experience on a daily basis.
Read Article
Gut-derived TNF: Connection Between Crohn’s and SpA and Sacroiliitis
The pathogenesis between microscopic gut inflammation leading to the development of Crohn’s disease and sacroiliitis has been poorly understood. Dr. Debusschere, et al sought to understand this important link between IBD and axial SpA.
Read Article
Reactive Arthritis
Prof Robert Inman gave a great summary of the state of the art in reactive arthritis (ReA).
Read Article
Key Takeaways from ACR Review Course
The ACR Review Course was superb once again from top to bottom, from Blue Fingers to Practical Treatment of RA. Every year I wonder if I should skip it, but each year I go. And I have never regretted it. Here are my take-home messages and “pearls” from the ACR Review Course.
Read Article
